S&P 500   3,244.71 (-2.14%)
DOW   26,786.90 (-1.84%)
QQQ   264.11 (-3.07%)
AAPL   107.34 (-4.00%)
MSFT   201.10 (-3.05%)
FB   248.94 (-2.28%)
GOOGL   1,408.93 (-3.49%)
AMZN   3,007.23 (-3.89%)
NVDA   486.64 (-3.73%)
TSLA   376.64 (-11.22%)
BABA   272.36 (-1.06%)
CGC   14.45 (-9.91%)
GE   6.13 (-1.92%)
MU   49.82 (+0.24%)
AMD   74.75 (-3.80%)
T   27.98 (-1.86%)
F   6.66 (-1.77%)
ACB   5.17 (-29.37%)
GILD   63.36 (-0.06%)
NFLX   471.43 (-4.02%)
DIS   123.13 (-3.21%)
BAC   23.45 (-2.05%)
BA   151.11 (-3.63%)
S&P 500   3,244.71 (-2.14%)
DOW   26,786.90 (-1.84%)
QQQ   264.11 (-3.07%)
AAPL   107.34 (-4.00%)
MSFT   201.10 (-3.05%)
FB   248.94 (-2.28%)
GOOGL   1,408.93 (-3.49%)
AMZN   3,007.23 (-3.89%)
NVDA   486.64 (-3.73%)
TSLA   376.64 (-11.22%)
BABA   272.36 (-1.06%)
CGC   14.45 (-9.91%)
GE   6.13 (-1.92%)
MU   49.82 (+0.24%)
AMD   74.75 (-3.80%)
T   27.98 (-1.86%)
F   6.66 (-1.77%)
ACB   5.17 (-29.37%)
GILD   63.36 (-0.06%)
NFLX   471.43 (-4.02%)
DIS   123.13 (-3.21%)
BAC   23.45 (-2.05%)
BA   151.11 (-3.63%)
S&P 500   3,244.71 (-2.14%)
DOW   26,786.90 (-1.84%)
QQQ   264.11 (-3.07%)
AAPL   107.34 (-4.00%)
MSFT   201.10 (-3.05%)
FB   248.94 (-2.28%)
GOOGL   1,408.93 (-3.49%)
AMZN   3,007.23 (-3.89%)
NVDA   486.64 (-3.73%)
TSLA   376.64 (-11.22%)
BABA   272.36 (-1.06%)
CGC   14.45 (-9.91%)
GE   6.13 (-1.92%)
MU   49.82 (+0.24%)
AMD   74.75 (-3.80%)
T   27.98 (-1.86%)
F   6.66 (-1.77%)
ACB   5.17 (-29.37%)
GILD   63.36 (-0.06%)
NFLX   471.43 (-4.02%)
DIS   123.13 (-3.21%)
BAC   23.45 (-2.05%)
BA   151.11 (-3.63%)
S&P 500   3,244.71 (-2.14%)
DOW   26,786.90 (-1.84%)
QQQ   264.11 (-3.07%)
AAPL   107.34 (-4.00%)
MSFT   201.10 (-3.05%)
FB   248.94 (-2.28%)
GOOGL   1,408.93 (-3.49%)
AMZN   3,007.23 (-3.89%)
NVDA   486.64 (-3.73%)
TSLA   376.64 (-11.22%)
BABA   272.36 (-1.06%)
CGC   14.45 (-9.91%)
GE   6.13 (-1.92%)
MU   49.82 (+0.24%)
AMD   74.75 (-3.80%)
T   27.98 (-1.86%)
F   6.66 (-1.77%)
ACB   5.17 (-29.37%)
GILD   63.36 (-0.06%)
NFLX   471.43 (-4.02%)
DIS   123.13 (-3.21%)
BAC   23.45 (-2.05%)
BA   151.11 (-3.63%)
Log in
NASDAQ:XLRN

Acceleron Pharma Price Target, Predictions & Analyst Ratings

$111.75
+2.35 (+2.15 %)
(As of 09/23/2020 03:06 PM ET)
Add
Compare
Today's Range
$108.89
Now: $111.75
$112.87
50-Day Range
$89.13
MA: $96.42
$107.14
52-Week Range
$37.60
Now: $111.75
$110.75
Volume12,508 shs
Average Volume643,024 shs
Market Capitalization$6.69 billion
P/E RatioN/A
Dividend YieldN/A
Beta0.71

Analyst Ratings

Acceleron Pharma (NASDAQ:XLRN) Price Target and Consensus Rating

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
14 Wall Street analysts have issued ratings and price targets for Acceleron Pharma in the last 12 months. Their average twelve-month price target is $120.57, predicting that the stock has a possible upside of 7.89%. The high price target for XLRN is $155.00 and the low price target for XLRN is $71.00. There are currently 1 sell rating, 1 hold rating, 11 buy ratings and 1 strong buy rating for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
XLRN Consensus Rating: BuyBuyBuyBuy
XLRN Consensus Rating Score: 2.862.862.772.86
XLRN Analyst Ratings: 1 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
1 Strong Buy Rating(s)
1 Sell Rating(s)
1 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
2 Hold Rating(s)
12 Buy Rating(s)
0 Strong Buy Rating(s)
XLRN Consensus Price Target: $120.57$120.57$117.62$98.85
XLRN Price Target Upside: 7.89% upside34.57% upside17.91% upside15.89% upside

Acceleron Pharma (NASDAQ:XLRN) Consensus Price Target History

Average Share Price and Price Target by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Acceleron Pharma (NASDAQ:XLRN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/24/2020Raymond JamesInitiated CoverageStrong-Buy$155.00Medium
8/7/2020Credit Suisse GroupBoost Price TargetOutperform$134.00 ➝ $135.00High
8/7/2020SVB LeerinkBoost Price TargetOutperform$132.00 ➝ $134.00High
7/15/2020Morgan StanleyBoost Price TargetOverweight$122.00 ➝ $123.00Low
7/7/2020Piper SandlerLower Price TargetOverweight$135.00 ➝ $130.00Low
6/25/2020CowenBoost Price TargetOutperform$121.00 ➝ $140.00High
6/25/2020Royal Bank of CanadaBoost Price TargetSector Perform$72.00 ➝ $99.00High
6/25/2020OppenheimerReiterated RatingBuy$115.00 ➝ $120.00High
6/2/2020CitigroupBoost Price TargetBuy$136.00 ➝ $137.00High
5/12/2020BarclaysReiterated RatingBuy$116.00High
5/12/2020JPMorgan Chase & Co.Boost Price TargetOverweight$108.00 ➝ $118.00High
5/4/2020HC WainwrightReiterated RatingBuy$137.00High
4/6/2020Goldman Sachs GroupDowngradeNeutral ➝ Sell$73.00High
10/21/2019Piper Jaffray CompaniesSet Price TargetBuy$71.00Low
4/22/2019CIBCReiterated RatingOutperform ➝ OutperformLow
7/10/2018UBS GroupBoost Price TargetBuy$62.00High
(Data available from 9/23/2018 forward)
This page was last updated on 9/23/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.